EP2812451A4 - Verfahren und zusammensetzungen in zusammenhang mit ros1-fusionen zur diagnostizierung und behandlung von krebs - Google Patents

Verfahren und zusammensetzungen in zusammenhang mit ros1-fusionen zur diagnostizierung und behandlung von krebs

Info

Publication number
EP2812451A4
EP2812451A4 EP13746869.0A EP13746869A EP2812451A4 EP 2812451 A4 EP2812451 A4 EP 2812451A4 EP 13746869 A EP13746869 A EP 13746869A EP 2812451 A4 EP2812451 A4 EP 2812451A4
Authority
EP
European Patent Office
Prior art keywords
ros1
fusions
diagnosing
methods
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13746869.0A
Other languages
English (en)
French (fr)
Other versions
EP2812451A2 (de
Inventor
David Hout
John Handshoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Genetics Inc
Original Assignee
Insight Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Genetics Inc filed Critical Insight Genetics Inc
Publication of EP2812451A2 publication Critical patent/EP2812451A2/de
Publication of EP2812451A4 publication Critical patent/EP2812451A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP13746869.0A 2012-02-08 2013-02-08 Verfahren und zusammensetzungen in zusammenhang mit ros1-fusionen zur diagnostizierung und behandlung von krebs Withdrawn EP2812451A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596720P 2012-02-08 2012-02-08
PCT/US2013/025345 WO2013119950A2 (en) 2012-02-08 2013-02-08 Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer

Publications (2)

Publication Number Publication Date
EP2812451A2 EP2812451A2 (de) 2014-12-17
EP2812451A4 true EP2812451A4 (de) 2016-01-06

Family

ID=48948165

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13746869.0A Withdrawn EP2812451A4 (de) 2012-02-08 2013-02-08 Verfahren und zusammensetzungen in zusammenhang mit ros1-fusionen zur diagnostizierung und behandlung von krebs

Country Status (5)

Country Link
EP (1) EP2812451A4 (de)
JP (1) JP2015508644A (de)
CN (1) CN104364391A (de)
AU (1) AU2013216904A1 (de)
WO (1) WO2013119950A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201601850YA (en) 2013-09-10 2016-04-28 Univ Texas Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
EP3825421B1 (de) 2014-03-25 2022-06-22 Quest Diagnostics Investments Incorporated Nachweis von genfusionen durch intragene differenzielle expression (ide) unter verwendung von zyklischen schwellen
US10082496B2 (en) * 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
CN104830989A (zh) * 2015-05-25 2015-08-12 上海允英医疗科技有限公司 一种用于ros1与多种基因发生融合突变的检测试剂盒
US20190071730A9 (en) * 2015-07-21 2019-03-07 Guardant Health, Inc. Locked nucleic acids for capturing fusion genes
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
EP3697390A1 (de) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmazeutische zusammensetzungen und darreichungsformen
EP3863636A1 (de) * 2018-10-08 2021-08-18 Revolution Medicines, Inc. Shp2-inhibitor-zusammensetzungen zur verwendung in der behandlung von krebs
WO2024072805A1 (en) * 2022-09-26 2024-04-04 Lau, Johnson Yiu-Nam Compositions, systems, and methods for detection of ovarian cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084631A2 (en) * 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454994A1 (de) * 2003-03-07 2004-09-08 Université de la Méditerranée Standardisiertes und optimiertes quantitatives Reverse-Transkriptase-Echtzeit-Polymerasekettenreaktionsverfahren zum Nachweis von minimalen Resterkrankungen bei Leukämie
US20100143918A1 (en) * 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US9364477B2 (en) * 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
EP2432900A4 (de) * 2009-05-15 2012-11-21 Insight Genetics Inc Verfahren und zusammensetzungen in zusammenhang mit alk-fusionen zur diagnostizierung und behandlung von krebs
EP2586862B9 (de) * 2010-06-22 2016-07-13 LSI Medience Corporation Verfahren zum nachweis eines neuen ros1-fusionsprodukts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084631A2 (en) * 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENGUANG LI ET AL: "Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers", PLOS ONE, vol. 6, no. 11, 30 November 2011 (2011-11-30), pages e28204, XP055209333, DOI: 10.1371/journal.pone.0028204 *

Also Published As

Publication number Publication date
WO2013119950A2 (en) 2013-08-15
EP2812451A2 (de) 2014-12-17
WO2013119950A3 (en) 2014-11-13
CN104364391A (zh) 2015-02-18
AU2013216904A1 (en) 2014-08-28
JP2015508644A (ja) 2015-03-23

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
EP2812451A4 (de) Verfahren und zusammensetzungen in zusammenhang mit ros1-fusionen zur diagnostizierung und behandlung von krebs
IL237791B (en) A method for treating cancer
HK1200739A1 (en) Diagnostic methods and compositions for treatment of cancer
EP2890815A4 (de) Verfahren zur diagnose und behandlung von krebs
SG11201503893RA (en) Method of treating cancer
IL238177A0 (en) Methods and preparations for the treatment of cancer
DK3292875T3 (en) Compositions and methods for treating diseases
IL234606B (en) Innovative methods and compounds for the treatment of diseases
HK1205254A1 (en) Methods of treatment of cancer
EP2895206A4 (de) Verfahren zur behandlung von karzinomen
IL238592A0 (en) Methods for treating liver diseases
HK1208805A1 (en) Inhibitors of beta hydrolase for treatment of cancer
EP2928456A4 (de) Verfahren und zusammensetzungen für die behandlung von krebs
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
HK1206633A1 (en) Composition for treatment of warts
ZA201107399B (en) Method and compositions for treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140905

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20151207

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20151201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160715